LBRX at a glance
LB PHARMACEUTICALS INC (LBRX, SEC CIK 1691082) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding LB PHARMACEUTICALS INC (LBRX) shares worth $314.5 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Deep Track Biotechnology Master Fund, Ltd. on July 30, 2026 of 286,205 shares at $34.94 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 24 funds
- $314.5M · +1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added AI risk: EU AI Act exposure, with noncompliance fines up to €35 million or 7% of worldwide annual turnover
- Most material update, financial reporting: Unremediated internal-control weaknesses, with remediation targeted by December 31, 2026
- Regulatory risk: FDA may reject Phase 2 acute-schizophrenia data as one of two pivotal NDA trials
- Operational risk: Clinical-trial enrollment delays or withdrawals could compromise data quality and extend development timelines
- Liquidity risk: $403.8 million in cash, equivalents and short-term investments funds operations for at least 12 months, but additional capital remains required
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales
- Net loss $59.1M vs $3.6M YoY, operating loss $62.5M vs $5.2M
- R&D highest spending area: $51.5M, up from $2.4M, driven by schizophrenia trials
- Cash, equivalents and short-term investments $403.8M at September 30, 2026
- Operating cash use $125.2M, financing provided $234.7M, investments used $144.6M
- Outlook: continued losses, cash runway beyond Q2 2029, clinical development and expenses rising significantly
AI summary of the LBRX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers quarterly financial results for the period ended September 30, 2026
- Exhibit 99.1 contains the detailed results investors need to assess performance and financial condition
Item EX-99.1: Item EX-99.1
- Q3 2026 R&D spending rose to $51.5M from $2.4M, reflecting accelerated Phase 3 and Phase 2 development
- Net loss widened to $59.1M from $3.6M, increasing clinical-stage cash burn
Item EX-99.1: Item EX-99.1
- Susan G. Kozauer appointed Chief Medical Officer, strengthening clinical and regulatory leadership
- Prior CAPLYTA development experience spans schizophrenia, mood disorders, pediatric indications, and multiple FDA approvals
Item 7.01: Regulation FD Disclosure
- Dr. Kozauer appointed Chief Medical Officer, strengthening clinical-development leadership
- Appointment may influence trial execution, regulatory strategy and investor confidence
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Susan G. Kozauer appointed Chief Medical Officer effective September 14, 2026, strengthening clinical-development leadership
- Prior experience at Centessa Pharmaceuticals and Intra-Cellular Therapies, relevant to advancing the Company’s pipeline
Item EX-99.1: Item EX-99.1
- Joseph Miller appointed CFO, adding commercialization and public-biotech finance experience ahead of pivotal NOVA-2 results
- Miller previously supported Aurinia Pharmaceuticals through LUPKYNIS launch and commercial infrastructure expansion
Item 7.01: Regulation FD Disclosure
- CFO appointment announced for Mr. Miller, making him responsible for financial reporting, capital planning, and investor communications
- Leadership transition may affect financial strategy and execution, depending on Mr. Miller’s background
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Joseph M. Miller appointed CFO effective September 2, 2026, bringing public biotech and commercial-stage finance experience
- Initial base salary $530,000, with target annual bonus equal to 40% of salary
AI summaries of LBRX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LBRX
Don't miss the next LBRX filing
- Alerts as it files. A push when LBRX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LBRX, by share count.
- Ask anything. An AI agent that reads every LBRX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kozauer Susan Gani | A | Oct 9, 2026 | 200,000 | - |
| Miller Joseph M | A | Oct 9, 2026 | 200,000 | - |
| Deep Track Biotechnology Master Fund, Ltd. | Buy | Jul 30, 2026 | 286,205 | $34.94 |
| Hemrajani Rekha | A | Jun 3, 2026 | 10,000 | - |
| Nussbaum Ran | A | Jun 3, 2026 | 10,000 | - |
| Lenz Robert A. | A | Jun 3, 2026 | 12,500 | - |
| RUFFOLO ROBERT R | A | Jun 3, 2026 | 10,000 | - |
| Luse Rebecca | A | Jun 3, 2026 | 10,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Net Income | - | -$63.1M | -$25.2M |
| Balance Sheet | |||
| Total Assets | - | $33.5M | $312.9M |
| Equity | -$34.5M | -$94.6M | $301.3M |
| ROE | - | 66.7% | -8.4% |
| Per Share | |||
| EPS | - | $-176.15 | $-3.13 |
| Cash Flow | |||
| Operating CF | - | -$53.1M | -$35.2M |
| CapEx | - | $769K | $52K |
Source: XBRL data in LB PHARMACEUTICALS INC (LBRX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate LBRX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $314.5M |
| Q2 2026 | 23 | $258.8M |
| Q1 2026 | 20 | $169.9M |
| Q4 2025 | 17 | $148.0M |
| Q3 2025 | 12 | $82.4M |
- Goldman Sachs Group+387.9K (+67%)
- T. Rowe Price Group+331.9K (+1783%)
- Vanguard Capital Management LLC+128.7K (+13%)
- Two Sigma Investments+111.9K (+230%)
- State Street Corp+103.4K (+17%)
- BlackRock−387.5K (-14%)
- Ameriprise Financial−170.3K (-75%)
- Millennium Management−86.4K (-33%)
- JPMorgan Chase & Co−53.1K (-4%)
- Wells Fargo & Co−14.0K (-72%)
- Franklin Resources+9.1K
- Truist Financial+8.8K
- Prudential Financial+5.3K
- U.S. Bancorp+27
- FMR LLC (Fidelity)−188.9K
- Raymond James Financial−91.7K
- Fifth Third Bancorp−390
Source: 13F-HR filings on SEC EDGAR (aggregated from 96 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LBRX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Oct 13, 2026 | - | - | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 8-K | Sep 3, 2026 | - | Analysis | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 3, 2026 | - | - | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| SC 13G | Jul 16, 2026 | - | - | |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 8-K | Jun 9, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| SC 13G | May 15, 2026 | - | - | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-K | Mar 26, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
LBRX SEC filings: frequently asked questions
Which institutions hold LBRX stock?
As of September 30, 2026, the largest LB PHARMACEUTICALS INC (LBRX) holders among the 13F filers tracked by SignalX were BlackRock ($90.1 million), JPMorgan Chase & Co ($53.8 million), Vanguard Capital Management LLC ($42.2 million), Goldman Sachs Group ($37.0 million), State Street Corp ($27.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did LBRX report in its latest 8-K?
LB PHARMACEUTICALS INC (LBRX) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers quarterly financial results for the period ended September 30, 2026.
What are the latest LBRX SEC filings?
LB PHARMACEUTICALS INC (LBRX) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 13, 2026.
What is LBRX's SEC CIK number?
LB PHARMACEUTICALS INC (LBRX)'s SEC Central Index Key (CIK) is 1691082. EDGAR lists every LBRX filing under that number.
Ask anything about LBRX
The research agent reads LBRX's filings, financials, insider trades and 13F holders, then answers with sources.